Evidence map›Paper›PMID 30200495›Full record

ArticleNutrients2018

Ginsenoside Rh2 Ameliorates Lipopolysaccharide-Induced Acute Lung Injury by Regulating the TLR4/PI3K/Akt/mTOR, Raf-1/MEK/ERK, and Keap1/Nrf2/HO-1 Signaling Pathways in Mice.

Yung-Hung Hsieh, Jeng-Shyan Deng, Yuan-Shiun Chang, Guan-Jhong Huang

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Research Progress on the Anticancer Effect of Ginsenoside Rh1.Current issues in molecular biology · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Ginsenoside RhInternational journal of molecular sciences · 2024
    Article
  10. Research Progress of Bioactive Components inMolecules (Basel, Switzerland) · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Therapeutic Candidates for Alzheimer's Disease: Saponins.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yung-Hung HsiehDepartment of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 413, Taiwan. hyh3033@gmail.com.
Jeng-Shyan DengDepartment of Food Nutrition and Health Biotechnology, Asia University, Taichung 413, Taiwan. dengjs@asia.edu.tw.
Yuan-Shiun ChangDepartment of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 413, Taiwan. yschang@mail.cmu.edu.tw.
Guan-Jhong HuangDepartment of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 413, Taiwan. gjhuang@mail.cmu.edu.tw.
China Medical University · TWAsia University · TWKuang Tien General Hospital · TW

Funding

China Medical University Hospital ASIA104-CMUH-06
6 · The paper itself

Abstract

The anti-inflammatory effect of ginsenoside Rh2 (GRh2) has labeled it as one of the most important ginsenosides. The purpose of this study was to identify the anti-inflammatory and antioxidant effects of GRh2 using a lipopolysaccharide (LPS) challenge lung-injury animal model. GRh2 reduced LPS-induced proinflammatory mediator nitric oxide (NO), tumor necrosis factor-alpha, interleukin (IL)-1β, and anti-inflammatory cytokines (IL-4, IL-6, and IL-10) production in lung tissues. GRh2 treatment decreased the histological alterations in the lung tissues and bronchoalveolar lavage fluid (BALF) protein content; total cell number also reduced in LPS-induced lung injury in mice. Moreover, GRh2 blocked iNOS, COX-2, the phosphorylation of IκB-α, ERK, JNK, p38, Raf-1, and MEK protein expression, which corresponds with the growth of HO-1, Nrf-2, catalase, SOD, and GPx expression in LPS-induced lung injury. An in vivo experimental study suggested that GRh2 has anti-inflammatory effects, and has potential therapeutic efficacy in major anterior segment lung diseases.

Indexed as

EndotoxinsAcute Lung InjuryAnimalsAnti-Inflammatory AgentsAntioxidantsCytokinesDisease Models, AnimalExtracellular Signal-Regulated MAP KinasesGinsenosidesHeme Oxygenase-1Inflammation MediatorsKelch-Like ECH-Associated Protein 1LungMaleMAP Kinase Kinase KinasesMembrane ProteinsAnti-Inflammatory AgentsAntioxidantsCytokinesendotoxin, Escherichia coliEndotoxinsExtracellular Signal-Regulated MAP Kinasesginsenoside Rh2GinsenosidesHeme Oxygenase-1Hmox1 protein, mouseInflammation MediatorsKeap1 protein, mouseKelch-Like ECH-Associated Protein 1MAP Kinase Kinase KinasesMembrane ProteinsmTOR protein, mouseNfe2l2 protein, mouseNF-E2-Related Factor 2Phosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-rafTlr4 protein, mouseToll-Like Receptor 4TOR Serine-Threonine Kinasesacute lung injuryginsenoside Rh2lipopolysaccharideMEKNrf-2

Identifiers

PMID30200495
PMCPMC6163254
OpenAlexW2883090939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.